Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida, discussed the shift to targeted therapies in acute myeloid leukemia (AML).
The development of targeted therapies are powering a change in the treatment of acute myeloid leukemia (AML), said Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida.
Transcript
How has the landscape of AML treatment evolved in recent years, and what are the implications for managed care decision making?
Well, the landscape has definitely changed gradually, over time with the advent of lower intensity based therapies that have risen to standard of care for older, less fit patients. But perhaps more importantly, the development of targeted therapies that are felt to really change the overall outcome of these patients. Targeted therapies, again, FLT3 inhibitors, IDH inhibitors, and BCL2 inhibitors—like venetoclax—are, I think, at the forefront of the landscape of therapy changing, and we have a variety of new, exciting targeted types of drugs, immunotherapy drugs that are still somewhat in the pipeline, that are showing promise in early phase studies, and will eventually work their way into frontline therapy and become standard of care in that setting.
I think the impact of these therapies on cost and reimbursement is certainly something we have to be paying a lot of attention to, because these new drugs are expensive, and many of them can be given for a long time—perhaps months up to a few years. The traditional high cost of care in AML is related to hospital-based stays and the cost incurred with hospitalizations. As many of these newer treatments, especially the azanucleoside combinations with venetoclax or other targeted agents, are primarily outpatient based, that helps defray hospital costs—but on the other end of the scale, adds cost to pharmacy and outpatient related costs that may go on for a long time if the patient is responding and doing well.
Although it's fantastic that we're seeing new developments in leukemia, and new drugs that are helping patients live longer and live better, there certainly are cost concerns in the long term for these are these drugs that are very expensive and often require a lot of supportive care to go along with them to help maintain patient's quality of life—whether it's transfusion support in the short term, antibiotics, frequent visits, laboratory monitoring, those types of things.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More